SpliceBio raises $135 million to drive forward dual-vector gene therapy

Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene therapy, SB-007, and expand its broader pipeline of genetic medicines.

The Barcelona-based firm is currently enrolling patients into a Phase I/II trial of SB-007, which has been cleared by both the US regulator and the UK’s MHRA. The candidate is designed to restore a working version of the ABCA4 protein, targeting the genetic driver of Stargardt disease, an inherited condition that leads to progressive vision loss and currently has no approved treatments.

The platform behind SB-007 was developed at Princeton University and tackles a long-standing limitation in gene therapy: the size constraints of AAV vectors. Using a dual-vector approach, SpliceBio’s technology splits large genes and reassembles them within target cells using a proprietary protein splicing method.